{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:15:32Z","timestamp":1793643332598,"version":"4.5.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2009,7,7]],"date-time":"2009-07-07T00:00:00Z","timestamp":1246924800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1038\/nrrheum.2009.141","type":"journal-article","created":{"date-parts":[[2009,7,7]],"date-time":"2009-07-07T07:22:37Z","timestamp":1246951357000},"page":"433-441","source":"Crossref","is-referenced-by-count":153,"title":["B-cell-directed therapies for autoimmune disease"],"prefix":"10.1038","volume":"5","author":[{"given":"Thomas","family":"D\u00f6rner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Radbruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd R.","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,7,7]]},"reference":[{"key":"BFnrrheum2009141_CR1","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/00002281-200305000-00011","volume":"15","author":"T Dorner","year":"2003","unstructured":"Dorner, T. & Burmester, G. R. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr. Opin. Rheumatol. 15, 246\u2013252 (2003).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum2009141_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/40540","volume":"388","author":"RA Manz","year":"1997","unstructured":"Manz, R. A., Thiel, A. & Radbruch, A. Lifetime of plasma cells in the bone marrow. Nature 388, 133\u2013134 (1997).","journal-title":"Nature"},{"key":"BFnrrheum2009141_CR3","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1056\/NEJMoa066092","volume":"357","author":"IJ Amanna","year":"2007","unstructured":"Amanna, I. J., Carlson, N. E. & Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903\u20131915 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2009141_CR4","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nri1886","volume":"6","author":"A Radbruch","year":"2006","unstructured":"Radbruch, A. et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. 6, 741\u2013750 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnrrheum2009141_CR5","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JCW Edwards","year":"2004","unstructured":"Edwards, J. C. W. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572\u20132581 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2009141_CR6","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.rdc.2008.08.014","volume":"34","author":"X Mariette","year":"2008","unstructured":"Mariette, X. Therapeutic potential for B-cell modulation in Sj\u00f6gren's syndrome. Rheum. Dis. Clin. North Am. 34, 1025\u20131033 (2008).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"BFnrrheum2009141_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/nri1938","volume":"6","author":"D Tarlinton","year":"2006","unstructured":"Tarlinton, D. B-cell memory: are subsets necessary? Nat. Rev. Immunol. 6, 785\u2013790 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnrrheum2009141_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/35105052","volume":"1","author":"A Bendelac","year":"2001","unstructured":"Bendelac, A., Bonneville, M. & Kearney, J. F. Autoreactivity by design: innate B and T lymphocytes. Nat. Rev. Immunol. 1, 177\u2013186 (2001).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnrrheum2009141_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1146\/annurev.immunol.23.021704.115728","volume":"23","author":"S Pillai","year":"2005","unstructured":"Pillai, S., Cariappa, A. & Moran, S. T. Marginal zone B cells. Annu. Rev. Immunol. 23, 161\u2013196 (2005).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrrheum2009141_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.coi.2008.03.016","volume":"20","author":"D Tarlinton","year":"2008","unstructured":"Tarlinton, D., Radbruch, A., Hiepe, F. & Dorner, T. Plasma cell differentiation and survival. Curr. Opin. Immunol. 20, 162\u2013169 (2008).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnrrheum2009141_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jaut.2007.11.001","volume":"30","author":"A Binard","year":"2008","unstructured":"Binard, A. et al. Does BAFF dysregulation play a major role in the pathogenesis of systemic lupus erythematosus? J. Autoimmun. 30, 63\u201367 (2008).","journal-title":"J. Autoimmun."},{"key":"BFnrrheum2009141_CR12","doi-asserted-by":"publisher","first-page":"18466","DOI":"10.1073\/pnas.0808205105","volume":"105","author":"E Lindh","year":"2008","unstructured":"Lindh, E. et al. AIRE regulates T-cell-independent B-cell responses through BAFF. Proc. Natl Acad. Sci. USA 105, 18466\u201318471 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum2009141_CR13","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen, S. B. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54, 2793\u20132806 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009141_CR14","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"P Emery","year":"2006","unstructured":"Emery, P. et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment\u2014results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54, 1390\u20131400 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009141_CR15","first-page":"S645","volume":"50","author":"G Cambridge","year":"2004","unstructured":"Cambridge, G. et al. Serological changes following B cell depletion therapy in systemic lupus erythematosus: relationship with BLyS. Arthritis Rheum. 50, S645\u2013S646 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009141_CR16","first-page":"656","volume":"26","author":"CAE Walsh","year":"2008","unstructured":"Walsh, C. A. E., Fearon, U., FitzGerald, O., Veale, D. J. & Bresnihan, B. Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy. Clin. Exp. Rheumatol. 26, 656\u2013658 (2008).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum2009141_CR17","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1136\/ard.2007.080960","volume":"67","author":"RM Thurlings","year":"2008","unstructured":"Thurlings, R. M. et al. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann. Rheum. Dis. 67, 917\u2013925 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2009141_CR18","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1136\/ard.2007.074229","volume":"67","author":"A Kavanaugh","year":"2008","unstructured":"Kavanaugh, A. et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann. Rheum. Dis. 67, 402\u2013408 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2009141_CR19","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/art.22400","volume":"56","author":"K Vos","year":"2007","unstructured":"Vos, K. et al. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum. 56, 772\u2013778 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009141_CR20","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/art.11181","volume":"48","author":"G Cambridge","year":"2003","unstructured":"Cambridge, G. et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 48, 2146\u20132154 (2003).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009141_CR21","first-page":"S270","volume":"50","author":"KA Keogh","year":"2004","unstructured":"Keogh, K. A., Ytterberg, S. R., Fervenza, F. C. & Specks, U. Rituximab for remission induction in severe ANCA-associated vasculitis: report of a prospective open-label pilot trial in 10 patients [abstract]. Arthritis Rheum. 50, S270 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009141_CR22","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/ndt\/gfh599","volume":"20","author":"AJ Ferraro","year":"2005","unstructured":"Ferraro, A. J., Day, C. J., Drayson, M. T. & Savage, C. O. Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol. Dial. Transplant. 20, 622\u2013625 (2005).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrrheum2009141_CR23","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/ard.2007.079418","volume":"67","author":"G Cambridge","year":"2008","unstructured":"Cambridge, G. et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann. Rheum. Dis. 67, 1011\u20131016 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2009141_CR24","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.immuni.2007.09.002","volume":"27","author":"T Dorner","year":"2007","unstructured":"Dorner, T. & Radbruch, A. Antibodies and B cell memory in viral immunity. Immunity 27, 384\u2013392 (2007).","journal-title":"Immunity"},{"key":"BFnrrheum2009141_CR25","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/intimm\/2.6.487","volume":"2","author":"P Vieira","year":"1990","unstructured":"Vieira, P. & Rajewsky, K. Persistence of memory B-cells in mice deprived of T-cell help. Int. Immunol. 2, 487\u2013494 (1990).","journal-title":"Int. Immunol."},{"key":"BFnrrheum2009141_CR26","doi-asserted-by":"publisher","first-page":"5970","DOI":"10.4049\/jimmunol.165.10.5970","volume":"165","author":"M Odendahl","year":"2000","unstructured":"Odendahl, M. et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J. Immunol. 165, 5970\u20135979 (2000).","journal-title":"J. Immunol."},{"key":"BFnrrheum2009141_CR27","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/art.23473","volume":"58","author":"P Roll","year":"2008","unstructured":"Roll, P., Dorner, T. & Tony, H. P. Anti-CD20 therapy in patients with rheumatoid arthritis\u2014predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum. 58, 1566\u20131575 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009141_CR28","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1002\/art.22810","volume":"56","author":"JH Anolik","year":"2007","unstructured":"Anolik, J. H. et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 56, 3044\u20133056 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009141_CR29","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1182\/blood-2004-01-0346","volume":"104","author":"S Weller","year":"2004","unstructured":"Weller, S. et al. Human blood IgM \u201cmemory\u201d B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 104, 3647\u20133654 (2004).","journal-title":"Blood"},{"key":"BFnrrheum2009141_CR30","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1084\/jem.20022020","volume":"197","author":"S Kruetzmann","year":"2003","unstructured":"Kruetzmann, S. et al. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J. Exp. Med. 197, 939\u2013945 (2003).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum2009141_CR31","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.clim.2008.09.009","volume":"130","author":"L Martinez-Gamboa","year":"2009","unstructured":"Martinez-Gamboa, L. et al. Role of the spleen in peripheral memory B-cell homeostasis in patients with autoimmune thrombocytopenia purpura. Clin. Immunol. 130, 199\u2013212 (2009).","journal-title":"Clin. Immunol."},{"key":"BFnrrheum2009141_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1084\/jem.20052033","volume":"203","author":"M Tsuiji","year":"2006","unstructured":"Tsuiji, M. et al. A checkpoint for autoreactivity in human IgM+ memory B cell development. J. Exp. Med. 203, 393\u2013400 (2006).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum2009141_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/art.23178","volume":"58","author":"PP Tak","year":"2008","unstructured":"Tak, P. P. et al. Atacicept in patients with rheumatoid arthritis. Arthritis Rheum. 58, 61\u201372 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009141_CR34","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1002\/art.22070","volume":"54","author":"M Weinblatt","year":"2006","unstructured":"Weinblatt, M. et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs\u2014a one-year randomized, placebo-controlled study. Arthritis Rheum. 54, 2807\u20132816 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009141_CR35","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/BOR.0b013e3282f5e08d","volume":"20","author":"T Dorner","year":"2008","unstructured":"Dorner, T. & Burmester, G. R. New approaches of B-cell-directed therapy: beyond rituximab. Curr. Opin. Rheumatol. 20, 263\u2013268 (2008).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum2009141_CR36","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/ar1967","volume":"8","author":"R Eisenberg","year":"2006","unstructured":"Eisenberg, R. Targeting B cells in systemic lupus erythematosus: not just d\u00e9j\u00e0 vu all over again. Arthritis Res. Ther. 8, 108 (2006).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2009141_CR37","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/00002281-200405000-00003","volume":"16","author":"RJ Looney","year":"2004","unstructured":"Looney, R. J., Anolik, J. & Sanz, I. B cells as therapeutic targets for rheumatic diseases. Curr. Opin. Rheumatol. 16, 180\u2013185 (2004).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum2009141_CR38","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","volume":"40","author":"JCW Edwards","year":"2001","unstructured":"Edwards, J. C. W. & Cambridge, G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 40, 205\u2013211 (2001).","journal-title":"Rheumatology"},{"key":"BFnrrheum2009141_CR39","doi-asserted-by":"publisher","first-page":"S378","DOI":"10.1002\/art.10773","volume":"48","author":"MJ Leandro","year":"2003","unstructured":"Leandro, M. J. et al. Treatment of refractory lupus nephritis with B lymphocyte depletion [abstract]. Arthritis Rheum. 48, S378 (2003).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009141_CR40","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","volume":"359","author":"AJ Coles","year":"2008","unstructured":"Coles, A. J. et al. Alemtuzumab vs. interferon \u03b21a in early multiple sclerosis. N. Engl. J. Med. 359, 1786\u20131801 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2009141_CR41","first-page":"S66","volume":"54","author":"MC Genovese","year":"2006","unstructured":"Genovese, M. C. et al. Safety and clinical activity of ocrelizumab (a humanized antibody targeting CD20+ B cells) in combination with methotrexate (MTX) in moderate-severe rheumatoid arthritis (RA) patients (pts) (Ph I\/II ACTION study). Arthritis Rheum. 54, S66\u2013S67 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009141_CR42","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1600-065X.2008.00627.x","volume":"223","author":"GJ Silverman","year":"2008","unstructured":"Silverman, G. J. & Boyle, D. L. Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis. Immunol. Rev. 223, 175\u2013185 (2008).","journal-title":"Immunol. Rev."},{"key":"BFnrrheum2009141_CR43","doi-asserted-by":"publisher","first-page":"S227","DOI":"10.1002\/art.11432","volume":"50","author":"PP Sfikakis","year":"2004","unstructured":"Sfikakis, P. P. et al. Remission of proliferative lupus nephritis following anti-B cell therapy is preceded by downregulation of the T cell costimulatory molecule CD40-ligand [abstract]. Arthritis Rheum. 50, S227 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009141_CR44","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1182\/blood-2007-02-068999","volume":"110","author":"R Stasi","year":"2007","unstructured":"Stasi, R. et al. Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 110, 2924\u20132930 (2007).","journal-title":"Blood"},{"key":"BFnrrheum2009141_CR45","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.coi.2008.05.011","volume":"20","author":"RP Taylor","year":"2008","unstructured":"Taylor, R. P. & Lindorfer, M. A. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr. Opin. Immunol. 20, 444\u2013449 (2008).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnrrheum2009141_CR46","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1182\/blood-2002-02-0392","volume":"99","author":"R Stasi","year":"2002","unstructured":"Stasi, R., Stipa, E., Forte, V., Meo, P. & Amadori, S. To the editor: variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 99, 3872\u20133873 (2002).","journal-title":"Blood"},{"key":"BFnrrheum2009141_CR47","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S1074-7613(04)00112-8","volume":"20","author":"F Martin","year":"2004","unstructured":"Martin, F. & Chan, A. C. Pathogenic roles of B cells in human autoimmunity: insights from the clinic. Immunity 20, 517\u2013527 (2004).","journal-title":"Immunity"},{"key":"BFnrrheum2009141_CR48","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser, S. L. et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676\u2013688 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2009141_CR49","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1136\/ard.2007.083865","volume":"67","author":"S Dass","year":"2008","unstructured":"Dass, S. et al. Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann. Rheum. Dis. 67, 1541\u20131544 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2009141_CR50","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1002\/art.10541","volume":"46","author":"MJ Leandro","year":"2002","unstructured":"Leandro, M. J., Edwards, J. C., Cambridge, G., Ehrenstein, M. R. & Isenberg, D. A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46, 2673\u20132677 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009141_CR51","first-page":"38A","volume":"14","author":"KA Keogh","year":"2003","unstructured":"Keogh, K. A., Wylam, M. E., Fervenza, F. C. & Specks, U. Rituximab\u2014a novel mechanism-based therapy for refractory ANCA associated vasculitis. J. Am. Soc. Nephrol. 14, 38A\u201339A (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrrheum2009141_CR52","first-page":"4029","volume":"58","author":"JT Merrill","year":"2008","unstructured":"Merrill, J. T. et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the randomized, double-blind phase II\/III study EXPLORER. Arthritis Rheum. 58, 4029\u20134030 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009141_CR53","unstructured":"ClinicalTrials.gov: a service of the US National Institutes of Health. A study to evaluate the efficacy and safety of rituximab in subjects with ISN\/RPS Class III or IV lupus nephritis (LUNAR), [ online ]"},{"key":"BFnrrheum2009141_CR54","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1136\/ard.2006.067124","volume":"66","author":"KP Ng","year":"2007","unstructured":"Ng, K. P. et al. B cell depletion therapy in systemic lupus erythematosus: long term follow-up and predictors of response. Ann. Rheum. Dis. 66, 1259\u20131262 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2009141_CR55","first-page":"1245","volume":"35","author":"PJ Mease","year":"2008","unstructured":"Mease, P. J. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. J. Rheumatol. 35, 1245\u20131255 (2008).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2009141_CR56","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1055\/s-2007-986395","volume":"35","author":"H Wiendl","year":"2008","unstructured":"Wiendl, H. & Hohlfeld, R. Immunopathogenesis and therapy of inflammatory myopathies. Akt. Neurol. 35, 185\u2013191 (2008).","journal-title":"Akt. Neurol."},{"key":"BFnrrheum2009141_CR57","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/ncpneph0133","volume":"2","author":"AD Salama","year":"2006","unstructured":"Salama, A. D. & Pusey, C. D. Drug insight: rituximab in renal disease and transplantation. Nat. Clin. Pract. Nephrol. 2, 221\u2013230 (2006).","journal-title":"Nat. Clin. Pract. Nephrol."},{"key":"BFnrrheum2009141_CR58","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1002\/art.10345","volume":"46","author":"F Zaja","year":"2002","unstructured":"Zaja, F. et al. Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum. 46, 2252\u20132254 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009141_CR59","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/01.tp.0000295361.54648.b3","volume":"84","author":"MS Zand","year":"2007","unstructured":"Zand, M. S. Therapeutic antibody agents for B-cell immunomodulation in renal transplantation. Transplantation 84, S11\u2013S19 (2007).","journal-title":"Transplantation"},{"key":"BFnrrheum2009141_CR60","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11940-008-0007-z","volume":"10","author":"DM Wingerchuk","year":"2008","unstructured":"Wingerchuk, D. M. & Weinshenker, B. C. Neuromyelitis optica. Curr. Treat. Opt. Neurol. 10, 55\u201366 (2008).","journal-title":"Curr. Treat. Opt. Neurol."},{"key":"BFnrrheum2009141_CR61","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/01.mph.0000212991.64435.f0","volume":"28","author":"MR Pranzatelli","year":"2006","unstructured":"Pranzatelli, M. R. et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus\u2013myoclonus syndrome. J. Pediatr. Hematol. Oncol. 28, 585\u2013593 (2006).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"BFnrrheum2009141_CR62","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.coph.2005.01.010","volume":"5","author":"JP Sieb","year":"2005","unstructured":"Sieb, J. P. Myasthenia gravis: emerging new therapy options. Curr. Opin. Pharmacol. 5, 303\u2013307 (2005).","journal-title":"Curr. Opin. Pharmacol."},{"key":"BFnrrheum2009141_CR63","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1111\/j.1529-8019.2008.00194.x","volume":"21","author":"M Sorce","year":"2008","unstructured":"Sorce, M., Arico, M. & Bongiorno, M. R. Rituximab in refractory pemphigus vulgaris. Dermatol. Ther. 21, S6\u2013S9 (2008).","journal-title":"Dermatol. Ther."},{"key":"BFnrrheum2009141_CR64","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000106585","volume":"215","author":"N Wallet-Faber","year":"2007","unstructured":"Wallet-Faber, N. et al. Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab. Dermatology 215, 252\u2013255 (2007).","journal-title":"Dermatology"},{"key":"BFnrrheum2009141_CR65","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1365-2141.2008.07054.x","volume":"141","author":"B Garvey","year":"2008","unstructured":"Garvey, B. Rituximab in the treatment of autoimmune haematological disorders. Br. J. Haematol. 141, 149\u2013169 (2008).","journal-title":"Br. J. Haematol."},{"key":"BFnrrheum2009141_CR66","first-page":"173","volume":"12","author":"A Wache","year":"2008","unstructured":"Wache, A., Gil, L. & Komarnicki, M. Rituximab in haematology and oncology in 10 years of experience. Wspolczesna Onkol. Contemp. Oncol. 12, 173\u2013178 (2008).","journal-title":"Wspolczesna Onkol. Contemp. Oncol."},{"key":"BFnrrheum2009141_CR67","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1179\/acb.2007.085","volume":"62","author":"A Verlinden","year":"2007","unstructured":"Verlinden, A. et al. Treatment of mixed type autoimmune haemolytic anaemia with autologous peripheral blood stem cell transplantation resulting in disappearance of the warm-type antibody and clinical remission of haemolysis. Acta Clin. Belg. 62, 380 (2007).","journal-title":"Acta Clin. Belg."},{"key":"BFnrrheum2009141_CR68","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/10428190500286481","volume":"47","author":"C Schollkopf","year":"2006","unstructured":"Schollkopf, C. et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk. Lymphoma 47, 253\u2013260 (2006).","journal-title":"Leuk. Lymphoma"},{"key":"BFnrrheum2009141_CR69","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1365-2516.2005.01060.x","volume":"11","author":"A Aggarwal","year":"2005","unstructured":"Aggarwal, A. et al. Rituximab for autoimmune haemophilia: a proposed treatment algorithm. Haemophilia 11, 13\u201319 (2005).","journal-title":"Haemophilia"},{"key":"BFnrrheum2009141_CR70","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3324\/haematol.10553","volume":"92","author":"WR Sperr","year":"2007","unstructured":"Sperr, W. R., Lechner, K. & Pabinger, I. Rituximab for the treatment of acquired antibodies to factor VIII. Haematologica 92, 66\u201371 (2007).","journal-title":"Haematologica"},{"key":"BFnrrheum2009141_CR71","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1182\/blood.V98.4.952","volume":"98","author":"R Stasi","year":"2001","unstructured":"Stasi, R., Pagano, A., Stipa, E. & Amadori, S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98, 952\u2013957 (2001).","journal-title":"Blood"},{"key":"BFnrrheum2009141_CR72","doi-asserted-by":"crossref","unstructured":"Dorner, T. et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther. 8, (2006).","DOI":"10.1186\/ar1942"},{"key":"BFnrrheum2009141_CR73","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/ard.2003.020172","volume":"64","author":"SD Steinfeld","year":"2005","unstructured":"Steinfeld, S. D. et al. Initial clinical study of immunotherapy in primary Sj\u00f6gren's syndrome with humanized anti-CD22 antibody epratuzumab. Ann. Rheum. Dis. 64, 311 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2009141_CR74","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1136\/ard.2007.075762","volume":"67","author":"AM Jacobi","year":"2008","unstructured":"Jacobi, A. M. et al. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann. Rheum. Dis. 67, 450\u2013457 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2009141_CR75","unstructured":"[No authors listed]. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator. Drugs RD 9, 197\u2013202 (2008)."},{"key":"BFnrrheum2009141_CR76","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1002\/art.23047","volume":"56","author":"M Dall'Era","year":"2007","unstructured":"Dall'Era, M. et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus. Arthritis Rheum. 56, 4142\u20134150 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009141_CR77","first-page":"4042","volume":"54","author":"M Dall'Era","year":"2006","unstructured":"Dall'Era, M. et al. Trial of atacicept in patients with systemic lupus erythematosus (SLE). Arthritis Rheum. 54, 4042\u20134043 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009141_CR78","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/art.23178","volume":"58","author":"PP Tak","year":"2008","unstructured":"Tak, P. P. et al. Atacicept in patients with rheumatoid arthritis. Arthritis Rheum. 58, 61\u201372 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009141_CR79","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nm1763","volume":"14","author":"K Neubert","year":"2008","unstructured":"Neubert, K. et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 14, 748\u2013755 (2008).","journal-title":"Nat. Med."},{"key":"BFnrrheum2009141_CR80","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1517\/14712598.7.9.1287","volume":"7","author":"T Dorner","year":"2007","unstructured":"Dorner, T. & Lipsky, P. E. B-cell targeting: a novel approach to immune intervention today and tomorrow. Exp. Opin. Biol. Ther. 7, 1287\u20131299 (2007).","journal-title":"Exp. Opin. Biol. Ther."},{"key":"BFnrrheum2009141_CR81","first-page":"S2","volume":"41","author":"T Alexander","year":"2008","unstructured":"Alexander, T. et al. Depletion of the autoreactive immunological memory followed by autologous haemopoietic stem cell transplantation in patients with refractory SLE induces long-term remissions through de novo generation of a juvenile and tolerant immune system. Bone Marrow Transplant. 41, S2\u2013S3 (2008).","journal-title":"Bone Marrow Transplant."},{"key":"BFnrrheum2009141_CR82","first-page":"18","volume":"33","author":"AF Kavanaugh","year":"2006","unstructured":"Kavanaugh, A. F. B cell targeted therapies: safety considerations. J. Rheumatol. 33, 18\u201323 (2006).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2009141_CR83","unstructured":"US Department of Health & Human Services Postmarketing Reviews\u2014Volume 1, Number 1, Fall 2007. Rituximab (marketed as Rituxan\u00ae): progressive multifocal leukoencephalopathy (PML), [ online ]"},{"key":"BFnrrheum2009141_CR84","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1002\/art.22657","volume":"56","author":"LH Calabrese","year":"2007","unstructured":"Calabrese, L. H., Molloy, E. S., Huang, D. R. & Ransohoff, R. M. Progressive multifocal leukoencephalopathy in rheumatic diseases\u2014evolving clinical and pathologic patterns of disease. Arthritis Rheum. 56, 2116\u20132128 (2007).","journal-title":"Arthritis Rheum."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2009.141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2009.141","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2009.141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T18:49:08Z","timestamp":1739213348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2009.141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,7]]},"references-count":84,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["BFnrrheum2009141"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2009.141","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,7]]}}}